Login / Signup

Efficacy and immune modulation associated with the addition of IMiDs to Daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic activity.

Ioannis V KostopoulosDespina FotiouMaria GavriatopoulouPantelis RousakisIoannis Ntanasis-StathopoulosChrysanthi PanteliPanagiotis MalandrakisMagdalini MigkouNikolaos AngelisNikolaos KanelliasEvangelos Eleutherakis-PapaiakovouFoteini TheodorakakouMaria KrevvataEvangelos TerposMeletios- Athanasios DimopoulosOurania E TsitsilonisEfstathios Kastritis
Published in: Blood cancer journal (2024)
Keyphrases
  • multiple myeloma
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • patient reported
  • drug induced
  • electronic health record